Indazole-3-carboxamides and their use as Wnt/β-catenin signaling pathway inhibitors
AssigneeSamumed, LLC
InventorsJohn Hood, Sunil Kumar KC
Life of this patent
Estimating the term…
Abstract
Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
Claims23
A compound or pharmaceutically acceptable salt thereof having the structure of Formula Ia:
- wherein:
- R3 is selected from the group consisting of 3-pyridylR6, 5-pyrimidinylR6, and 4-pyridazinylR6;
- R5 is selected from the group consisting of -heteroarylR7;
- R6 is a substituent selected from the group consisting of —(C1-2 alkyl)heterocyclylR8 and -heterocyclylR8;
- R7 is 1-2 substituents each independently selected from the group consisting of H, C1-3 alkyl, halide, —NH2, —OCF3, —CF3, —CN, —OR10, —(C1-2 alkyl)heterocyclylR9, -heterocyclylR9, and —SO2R11;
- R8 is 1-2 substituents each independently selected from the group consisting of H, C1-3 alkyl, halide, and —OR12;
- each R9 is 1-2 substituents each independently selected from the group consisting of H, C1-3 alkyl, halide, amino, —OCF3, —CF3, —CN, and —OR12;
- R10 is selected from the group consisting of H and C1-3 alkyl;
- R11 is C1-3 alkyl;
- and
- each R12 is independently selected from the group consisting of H and C1-3 alkyl.
A compound or pharmaceutically acceptable salt thereof having the structure of Formula Ia:
- wherein:
- R3 is 3-pyridylR6;
- R5 is selected from the group consisting of pyridylR7, -pyrimidinylR7, and -pyridazinylR7;
- R6 is —CH2heterocyclylR8;
- R7 is 1-2 substituents each independently selected from the group consisting of H, F, methyl, —NH2, —CF3, —CN, —OMe, —SO2Me,
- R8 is 1-2 substituents each independently selected from the group consisting of H and halide.
Dependencies are inferred from the claim text.